Standard BioTools Inc. (LAB)
USD 1.99
(-10.18%)
USD 1.99
(-10.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -76.6 Million USD | 45.75% |
| 2022 | -116.2 Million USD | -72.26% |
| 2021 | -67.45 Million USD | -32.18% |
| 2020 | -51.03 Million USD | 1.55% |
| 2019 | -51.83 Million USD | -7.63% |
| 2018 | -48.16 Million USD | 17.47% |
| 2017 | -58.36 Million USD | 20.26% |
| 2016 | -73.19 Million USD | -45.93% |
| 2015 | -50.15 Million USD | 3.24% |
| 2014 | -51.83 Million USD | -188.78% |
| 2013 | -17.95 Million USD | 0.67% |
| 2012 | -18.07 Million USD | 2.67% |
| 2011 | -18.56 Million USD | -27.4% |
| 2010 | -14.57 Million USD | 19.2% |
| 2009 | -18.03 Million USD | 38.95% |
| 2008 | -29.54 Million USD | -25.58% |
| 2007 | -23.52 Million USD | -8.6% |
| 2006 | -21.66 Million USD | 0.0% |
| 2001 | -67.45 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -31.71 Million USD | 24.46% |
| 2024 Q1 | -38.73 Million USD | -159.86% |
| 2024 Q2 | -41.98 Million USD | -8.4% |
| 2023 Q2 | -17.44 Million USD | -5.16% |
| 2023 Q1 | -16.59 Million USD | 21.4% |
| 2023 FY | -63.03 Million USD | 45.75% |
| 2023 Q4 | -14.9 Million USD | 29.6% |
| 2023 Q3 | -21.17 Million USD | -21.34% |
| 2022 Q4 | -21.11 Million USD | 27.27% |
| 2022 Q2 | -38.56 Million USD | -40.21% |
| 2022 FY | -116.2 Million USD | -72.26% |
| 2022 Q3 | -29.02 Million USD | 24.73% |
| 2022 Q1 | -27.5 Million USD | -144.28% |
| 2021 FY | -67.45 Million USD | -32.18% |
| 2021 Q1 | -19.32 Million USD | -14.29% |
| 2021 Q2 | -17.26 Million USD | 10.62% |
| 2021 Q3 | -19.61 Million USD | -13.57% |
| 2021 Q4 | -11.25 Million USD | 42.59% |
| 2020 Q4 | -16.9 Million USD | -209.37% |
| 2020 Q1 | -14.94 Million USD | -62.75% |
| 2020 FY | -51.03 Million USD | 1.55% |
| 2020 Q2 | -13.72 Million USD | 8.14% |
| 2020 Q3 | -5.46 Million USD | 60.19% |
| 2019 Q2 | -14.63 Million USD | -3.03% |
| 2019 FY | -51.83 Million USD | -7.63% |
| 2019 Q1 | -14.2 Million USD | -27.77% |
| 2019 Q3 | -13.81 Million USD | 5.6% |
| 2019 Q4 | -9.18 Million USD | 33.55% |
| 2018 Q1 | -12.63 Million USD | -44.64% |
| 2018 FY | -48.16 Million USD | 17.47% |
| 2018 Q2 | -12.78 Million USD | -1.2% |
| 2018 Q3 | -11.62 Million USD | 9.05% |
| 2018 Q4 | -11.11 Million USD | 4.39% |
| 2017 FY | -58.36 Million USD | 20.26% |
| 2017 Q4 | -8.73 Million USD | 44.02% |
| 2017 Q3 | -15.6 Million USD | 5.37% |
| 2017 Q2 | -16.48 Million USD | 5.98% |
| 2017 Q1 | -17.53 Million USD | 0.91% |
| 2016 FY | -73.19 Million USD | -45.93% |
| 2016 Q1 | -18.86 Million USD | -37.81% |
| 2016 Q2 | -18.14 Million USD | 3.85% |
| 2016 Q3 | -18.48 Million USD | -1.88% |
| 2016 Q4 | -17.69 Million USD | 4.25% |
| 2015 Q4 | -13.69 Million USD | -75.47% |
| 2015 Q1 | -14 Million USD | -42.39% |
| 2015 Q2 | -14.65 Million USD | -4.7% |
| 2015 Q3 | -7.8 Million USD | 46.77% |
| 2015 FY | -50.15 Million USD | 3.24% |
| 2014 Q4 | -9.83 Million USD | 24.63% |
| 2014 FY | -51.83 Million USD | -188.78% |
| 2014 Q3 | -13.04 Million USD | -5.41% |
| 2014 Q2 | -12.37 Million USD | 25.35% |
| 2014 Q1 | -16.57 Million USD | -320.68% |
| 2013 FY | -17.95 Million USD | 0.67% |
| 2013 Q4 | -3.94 Million USD | 20.42% |
| 2013 Q3 | -4.95 Million USD | -24.11% |
| 2013 Q2 | -3.99 Million USD | 21.26% |
| 2013 Q1 | -5.06 Million USD | -45.06% |
| 2012 Q4 | -3.49 Million USD | 10.64% |
| 2012 Q2 | -4.38 Million USD | 30.19% |
| 2012 Q3 | -3.9 Million USD | 10.88% |
| 2012 Q1 | -6.28 Million USD | -110.91% |
| 2012 FY | -18.07 Million USD | 2.67% |
| 2011 FY | -18.56 Million USD | -27.4% |
| 2011 Q3 | -4.05 Million USD | 39.06% |
| 2011 Q1 | -4.87 Million USD | -142.69% |
| 2011 Q4 | -2.97 Million USD | 26.54% |
| 2011 Q2 | -6.65 Million USD | -36.41% |
| 2010 Q4 | -2.01 Million USD | 35.14% |
| 2010 Q3 | -3.09 Million USD | 26.67% |
| 2010 Q2 | -4.22 Million USD | 19.32% |
| 2010 Q1 | -5.23 Million USD | -38.32% |
| 2010 FY | -14.57 Million USD | 19.2% |
| 2009 Q4 | -3.78 Million USD | 0.0% |
| 2009 FY | -18.03 Million USD | 38.95% |
| 2008 FY | -29.54 Million USD | -25.58% |
| 2007 FY | -23.52 Million USD | -8.6% |
| 2006 FY | -21.66 Million USD | 0.0% |
| 2001 Q3 | -19.61 Million USD | 0.0% |
| 2001 FY | -67.45 Million USD | 0.0% |
| 2001 Q4 | -11.25 Million USD | 42.59% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -215.24 Million USD | 64.413% |
| Prenetics Global Limited | -52.51 Million USD | -45.867% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1662.54% |
| CareDx, Inc | -101.9 Million USD | 24.828% |
| Exact Sciences Corporation | -215.01 Million USD | 64.374% |
| Exagen Inc. | -22.83 Million USD | -235.421% |
| Inotiv, Inc. | -81.46 Million USD | 5.966% |
| Guardant Health, Inc. | -564.72 Million USD | 86.436% |
| Biodesix, Inc. | -41.34 Million USD | -85.284% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -2853.437% |
| Precipio, Inc. | -7.62 Million USD | -905.249% |
| iSpecimen Inc. | -11.16 Million USD | -585.805% |
| Natera, Inc. | -446.24 Million USD | 82.835% |
| Aspira Women's Health Inc. | -18.85 Million USD | -306.323% |
| 23andMe Holding Co. | -321.35 Million USD | 76.164% |
| Castle Biosciences, Inc. | -67.97 Million USD | -12.685% |
| Personalis, Inc. | -109.93 Million USD | 30.323% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 21.321% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -599.333% |
| OpGen, Inc. | -15.68 Million USD | -388.256% |
| T2 Biosystems, Inc. | -49.66 Million USD | -54.236% |
| Myriad Genetics, Inc. | -123.7 Million USD | 38.076% |
| ICON Public Limited Company | 956.15 Million USD | 108.011% |
| NeoGenomics, Inc. | -107.73 Million USD | 28.9% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1662.54% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 106.982% |
| RadNet, Inc. | 98.69 Million USD | 177.611% |
| MDxHealth SA | -27.32 Million USD | -180.309% |
| Psychemedics Corporation | -2.92 Million USD | -2522.39% |
| Illumina, Inc. | -1.06 Billion USD | 92.834% |
| Check-Cap Ltd. | -19.28 Million USD | -297.159% |
| Twist Bioscience Corporation | -220.83 Million USD | 65.313% |
| DarioHealth Corp. | -56.18 Million USD | -36.326% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -5.372% |
| Sera Prognostics, Inc. | -39.82 Million USD | -92.361% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -628.086% |
| OPKO Health, Inc. | -157.02 Million USD | 51.217% |
| Medpace Holdings, Inc. | 336.82 Million USD | 122.742% |
| Neogen Corporation | 58.66 Million USD | 230.576% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -644.906% |
| Prenetics Global Limited | -52.51 Million USD | -45.867% |
| Mainz Biomed B.V. | -26.64 Million USD | -187.487% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -860.715% |
| Trinity Biotech plc | -27.04 Million USD | -183.232% |
| Neuronetics, Inc. | -30.55 Million USD | -150.704% |
| Sotera Health Company | 276.69 Million USD | 127.684% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -860.715% |